IMMUNOTOXIN TREATMENT OF BLEPHAROSPASM AND STRAABISMUS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 19277
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1992
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Houston Biotechnology
3608 Research Forest Drive, The Woodlands, TX, 77381
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Thomas L Wallace
 (713) 363-0999
Business Contact
Phone: () -
Research Institution
N/A
Abstract
BLEPHAROSPASM AND STRABISMUS ARE CHRONIC, DEBILITATING, OCULAR SPASTIC DISORDERS CAUSED BY UNCONTROLLED OR BALANCED MUSCLE CONTRACTION. THE LONG-TERM OBJECTIVE OF THIS WORK IS TO CREATE A THERAPEUTIC AGENT THAT WILL ABLATE CHOLINERGIC NEURONS RESPONSIBLE FOR THE MUSCLE CONTRACTION IN BLEPHAROSPASM AND STRABISMUS, AND TO TREAT HUMANS WITH THESE CONDITIONS. THE SPECIFIC AIMS INPHASE I ARE TO PRODUCE A HYBRIDOMA THAT SECRETES MONOCLONAL ANTIBODIES AGAINST A SPECIFIC CHOLINERGIC, NERVE TERMINAL MOLECULE, AND TO THEN CREATE AN IMMUNOTOXIN BY CONJUGATING THE MONOCLONAL ANTIBODY TO RICIN A TOXIN. WHEN ADMINISTERED, THE IMMUNOTOXIN WILL BECOME INTERNALIZED IN THE CHOLINERGIC NERVE TERMINAL AND KILL THE CHOLINERGIC NERVE. THIS APPROACH HAS AN ADVANTAGE OVER PRESENT TREATMENTS IN THAT FEWER TREATMENTS WILL BE NEEDED AND THERE MAY BE A PERMANENT CURE. THERE ARE A NUMBER OF OTHER RELATED, NON-OCULAR SPASTIC DISORDERS FOR WHICH THIS IMMUNOTOXIN COULD ALSO BE USED. THIS IS THE FIRST TIME AN IMMUNOTOXIN HAS BEEN DEVISED TO TREAT THESE DISORDERS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government